Marketing biologics is smaller, leaner, and more data-driven than traditional pharma. With the focus often on specialist physicians and on patient populations in the tens of thousands-or even thousands-direct and digital media are the primary outreach channels over advertising and print. In our experience with biologics, advertising is a low priority compared to the Web, medical meetings, and alternative media. Sometimes there's no advertising at all.
Marketing biologics is smaller, leaner, and more data-driven than traditional pharma. With the focus often on specialist physicians and on patient populations in the tens of thousands—or even thousands—direct and digital media are the primary outreach channels over advertising and print. In our experience with biologics, advertising is a low priority compared to the Web, medical meetings, and alternative media. Sometimes there's no advertising at all.
Biologics are expensive, so the ever-present challenges of access and patient adherence become magnified. Payers want hard data—not a form letter asserting medical need—before they pay for biologics, even for first-ever compounds. Patients need hands-on guidance in navigating insurance and other access options, as well as continual reinforcement to stay on a product that represents five- or six-figure revenue per Rx. A full-service agency for a biologic has to help create solutions to these issues, not just execute them.
If the biologic discovery company is comarketing the product, the client relationship can be very different. Bringing 12 people to an input meeting is a good way to alienate a biologic company partner. Bringing an intriguing idea—however rough, untested, or unasked for—is a good way to gain the respect and support of both partners.
Cambridge BioMarketing is a full-service healthcare marketing communications agency located in Cambridge, MA.
Telephone: 617-225-0001
E-mail: info@cambridgebmg.com
Web site: cambridgebmg.com
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.